ImmunityBio's Q1 2026 product revenue rose 168% to $44.2 million, beating estimates, while the GAAP net loss widened to $632.8 million. The company is advancing a Phase 2 NHL trial and an sBLA for BCG-naïve NMIBC.
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
The U.S. FDA has accepted for filing a New Drug Application for tirabrutinib under the accelerated approval pathway for relapsed or refractory primary central nervous system lymphoma, setting a PDUFA action date of December 18, 2026. The submission is supported by Phase 2 PROSPECT study results showing a 67% overall response rate and 44% complete response rate. If approved, tirabrutinib would be the first BTK inhibitor commercially available in the U.S. for this indication.
The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.
Calls are growing to bring CAR-T cell therapy to New Zealand as the current trial is set to end later this year. There is no clear path to public availability.
WHO in January 2024 launched its first list of priority childhood cancer drug formulations, naming six medicines that still lack optimal child-friendly versions. The agency says about 400,000 children and adolescents develop cancer each year and is working to expand access to safe, effective paediatric formulations.
A phase 1 trial shows denileukin diftitox administered before CAR-T therapy has a favorable safety profile and encouraging efficacy in high-risk DLBCL patients, with an 86% overall response rate and 77% one-year progression-free survival. The treatment demonstrated consistent regulatory T-cell depletion, supporting its immunomodulatory mechanism. Larger controlled studies are needed to confirm these preliminary findings.
The FDA has granted fast track designation to QRX003 for Netherton Syndrome and IBI3003 for relapsed or refractory multiple myeloma, while also accepting regulatory applications for other therapies addressing serious conditions with unmet medical needs.
Researchers report advances in cancer treatment through three distinct approaches: repurposing a heart medication to target lymphoma enzymes, blocking stress proteins to enhance immunotherapy, and developing antibodies that restore immune system attacks on tumors.
The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07771361 |
BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07763210 |
Lazarus: IT Therapy for ICANS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07750886 |
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) |
RECRUITING | |
| NCT07730515 |
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07679919 |
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07652580 |
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma |
RECRUITING | |
| NCT07623850 |
A Phase I Study of JLM019 Injection |
RECRUITING | PHASE1 |
| NCT07614035 |
Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma |
NOT_YET_RECRUITING | |
| NCT07566377 |
Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
RECRUITING | PHASE2 |
| NCT07456371 |
PIC1 Injection Therapy for Relapsed/Refractory B-NHL |
RECRUITING | PHASE1 |
